Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico

• Estefanía Palma ^[1] ; Vicente González ^[2] ; Daniela Grünholz ^[2] ; María Landaeta ^[2] ; María Mallea ^[3] ; José Pérez ^[3] ; Tomás Armstrong ^[3]
  1. [1] Universidad de Los Andes

     Universidad de Los Andes

     Colombia

     
  2. [2] Hospital Militar Servicio de Inmunoreumatología
  3. [3] Hospital Militar Unidad de tratamiento intermedio

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 145, Nº. 2, 2017, págs. 260-263
• Idioma: español
• Títulos paralelos:
  • Shock as an adverse reaction to rituximab: Case report
• Enlaces
  • Texto completo
• Resumen

  • Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course. However, there have been reports of refractory cardiogenic shock simulating septic shock. We report an 81-year-old male with the diagnosis of ANCA associated vasculitis. Rituximab 500 mg was administered intravenously for a relapse. The infusion proceeded without incident. However, 24 hours after its administration the patient began with fever, chills, coughing and strong malaise. The patient was transferred to the critical patient unit where a septic shock was suspected and resuscitative measures were started. However, the fast response to moderate doses of vasoactive drugs and complementary tests did not support an infectious etiology for the shock. Antimicrobials were discontinued and systemic corticosteroids were maintained, achieving remission of the symptoms. Shock as an unusual adverse reaction to Rituximab was suspected.